The Immune Checkpoint Inhibitors Market is experiencing unprecedented global growth as demand for advanced cancer immunotherapies continues to rise. Valued at USD 48,983.90 million in 2024, the market is projected to expand at a strong CAGR of 17.60% from 2025 to 2032. These therapies, which target checkpoint proteins such as PD-1, PD-L1, and CTLA-4, are transforming cancer treatment by...